Engineered biomaterials for cancer immunotherapy

Lulu Cai; Jialu Xu; Zhenglin Yang; Rongsheng Tong; Ziliang Dong; Chao Wang; Kam W Leong

doi:10.1002/mco2.8

Engineered biomaterials for cancer immunotherapy

MedComm (2020). 2020 May 27;1(1):35-46. doi: 10.1002/mco2.8. eCollection 2020 Jun.

Authors

Lulu Cai¹, Jialu Xu², Zhenglin Yang³, Rongsheng Tong¹, Ziliang Dong², Chao Wang², Kam W Leong⁴

Affiliations

¹ Personalized Drug Therapy Key Laboratory of Sichuan Province Department of Pharmacy Sichuan Provincial People's Hospital School of Medicine University of Electronic Science and Technology of China Chengdu China.
² Institute of Functional Nano & Soft Materials (FUNSOM) Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices Soochow University Suzhou China.
³ Sichuan Provincial Key Laboratory for Human Disease Gene Study the Institute of Laboratory Medicine Sichuan Provincial People's Hospital School of Medicine University of Electronic Science and Technology of China Chengdu China.
⁴ Department of Biomedical Engineering Columbia University New York USA.

PMID: 34766108
PMCID: PMC8489675
DOI: 10.1002/mco2.8

Abstract

Although cancer immunotherapy is showing tremendous promise and has progressed to the clinic, it has only achieved sporadic efficacy, with only a fraction of patients benefitting from the therapy and with undesirable side effects due to poor selectivity and high doses. Localized delivery of immunomodulators to activate anticancer immunity in situ avoids overactivation of the systemic immune system and reduces side effects. Engineered biomaterials-implantable, injectable, or transdermal-fabricated into drug delivery devices are critical components for the development of localized cancer immunotherapies. In this review, we briefly summarize progress in the application of engineered biomaterials to the localized delivery of cancer immunotherapy.

Keywords: anticancer immunity; biomaterials; cancer immunotherapy; localized delivery.

Publication types

Review